Insider · CIK 0001969581
Shane Bohnen
officer
Files at TECH (BIO-TECHNE Corp). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | TECH BIO-TECHNE Corp | MOption exercise Common Stock | +1,718 | $0.00 | $0 | 4,912 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | FTax withholding Common Stock | -527 | $53.60 | $28k | 4,385 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | MOption exercise Restricted Stock Unitsderivative | -50 | $0.00 | $0 | 49 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | MOption exercise Restricted Stock Unitsderivative | -1,668 | $0.00 | $0 | 3,338 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | AGrant or award Performance Restricted Stock Unitsderivative | +13,992 | $0.00 | $0 | 13,992 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | AGrant or award Restricted Stock Unitsderivative | +6,996 | $0.00 | $0 | 6,996 | Aug 19, 2025 |
| Aug 15, 2025 | TECH BIO-TECHNE Corp | AGrant or award Stock Option (Right to Buy)derivative | +17,897 | $0.00 | $0 | 17,897 | Aug 19, 2025 |
| Apr 3, 2025 | TECH BIO-TECHNE Corp | MOption exercise Common Stock | +2,260 | $0.00 | $0 | 3,941 | Apr 7, 2025 |
| Apr 3, 2025 | TECH BIO-TECHNE Corp | FTax withholding Common Stock | -747 | $54.86 | $41k | 3,194 | Apr 7, 2025 |
| Apr 3, 2025 | TECH BIO-TECHNE Corp | MOption exercise Restricted Stock Unitsderivative | -2,260 | $0.00 | $0 | 2,259 | Apr 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.